Summit Therapeutics is trading 6.1% up now at $18.59 after partner Akeso reported updated HARMONi-2 results showing ivonescimab extended median overall survival versus pembrolizumab.
- Median overall survival was 30.8 months for ivonescimab versus 22.6 months for pembrolizumab, an 8.2-month benefit.
- Interim analysis showed a statistically significant hazard ratio of 0.73 and p=0.009.
- The oncology catalyst is outweighing broader September 14 market weakness.